5. Conclusion

It seems that, after a phase of enthusiasm for the development of nanoparticles, we are now witnessing a slowdown in the development of these health objects. The future of these objects will undoubtedly lie in the optimization of 3rd-generation nanoparticles, enabling effective targeting of cells (conjugated active ingredients and antibodies), the tissue of interest and/or opening up new therapeutic indications. . These objects are widely used to treat cancer, where the benefit/risk balance can tolerate certain side effects. The current "safer-by-design" approach aims in particular (but not exclusively) to design safer or less toxic nanoparticles...